
Experimental AML Vaccine Extends Survival in Trial
Adults with high-risk acute myeloid leukemia saw median survival of 24 months on galinpepimut-S versus under 15 months on standard options in a phase 3 trial.
This page covers cancer, from research and treatment advances to screening guidance. Reporting follows clinical trials, regulatory decisions and the bodies that set screening recommendations.

Adults with high-risk acute myeloid leukemia saw median survival of 24 months on galinpepimut-S versus under 15 months on standard options in a phase 3 trial.
November 16, 2026
New Antibody Gets Fast-Track for Childhood NeuroblastomaFamilies of children with newly diagnosed high-risk neuroblastoma may eventually see a new first-line option, though it is not yet approved.
November 16, 2026
Breast Cancer Biosimilar Gains FDA ApprovalPeople with HER2-positive breast cancer may eventually have a lower-cost option, with a US launch not expected until Q3 2028.
November 15, 2026
Plant Compounds Flagged as Ovarian Cancer LeadsWomen with ovarian cancer may one day benefit, but these computer-screened candidates have not yet been tested in laboratory or animal studies.
November 12, 2026
Lancet Research Summaries Now Span Key CancersClinicians and patients following breast, lung, prostate and other cancers can now find Lancet evidence organized by disease area.
November 11, 2026
Skin Cancer Rates Rise Across GenerationsWomen show steeper increases in squamous cell carcinoma across Australia and seven European registries, a trend linked to lifetime sun exposure.
November 7, 2026
Immunotherapy Pair Lowers PSA in Advanced Prostate CancerIn a small early trial, most men with heavily treated disease saw PSA drop at least 50%.
November 7, 2026
New Lymphoma Drug IKS03 to Show Updated DataEarly trial results in advanced B-cell lymphoma will be presented at the December 2026 ASH meeting.
November 7, 2026
Two Breast Cancer Drugs Linked to Better Kidney OutcomesIn women with advanced breast cancer and kidney disease, abemaciclib and ribociclib were tied to better results than palbociclib.
November 7, 2026
Virus Therapy Shrinks Skin Cancers in Early TrialAdults with advanced skin cancers saw tumor responses in a small early study of an intratumoral oncolytic virus.
November 6, 2026
Two-Target Immunotherapy Shows Early Promise in Eye CancerAdults with metastatic uveal melanoma may see a new combination trial open, based on early results from small patient groups.
This section tracks trial results and what they measured, drug and device approvals in major markets, changes to screening guidance, and research into causes and risk. It also follows the delivery side — access to treatment, cost and the capacity of the centers providing it. Trial design gets as much attention as the headline result, since the two are routinely conflated. Cost and availability increasingly determine which approved treatments patients actually receive.